Unbiased AI-powered news
Studies show links between heart function and brain health that influence cognitive decline, mental health conditions, and heart disease. These connections suggest potential changes in diagnostic and treatment approaches. The findings come from recent research reported by New Scientist.
Substrate placeholder — needs reviewResearch indicates connections between the heart and brain that affect cognitive decline, mental health, and heart disease. New Scientist reported on these links, which involve physiological interactions between cardiovascular and neurological systems. The article draws from multiple studies examining how heart conditions impact brain function and vice versa.
Cognitive decline, often associated with aging or conditions like dementia, shares pathways with heart disease. For instance, reduced blood flow from heart issues can limit oxygen to the brain, contributing to cognitive impairments. Mental health disorders, such as depression and anxiety, also correlate with cardiovascular risks through inflammation and stress responses.
brain communicate via the autonomic nervous system and vascular pathways.
Disruptions in heart rhythm or blood pressure can lead to brain changes over time. These interactions explain overlapping symptoms in patients with both cardiac and neurological issues. Mental health conditions may exacerbate heart problems through behavioral factors like poor diet or inactivity, though direct causal links require further investigation.
These findings point to integrated approaches for diagnosis.
Doctors may use combined cardiac and brain imaging to assess risks more accurately. Treatment could involve therapies targeting both systems, such as medications that address inflammation across organs. Patients with one condition are at higher risk for the others, affecting millions worldwide.
For example, heart failure patients often experience cognitive symptoms, while those with depression face increased heart attack risks. Future research aims to clarify these links through longitudinal studies.
Health organizations continue to monitor developments in this area.
Single source — no framing comparison available.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
washingtonpost.comFlooding along the Guadalupe River has killed at least one person in central Texas. The same area recorded more than 130 deaths in flash floods last summer. Governor Greg Abbott confirmed the fatality in a Thursday update.
dailywire.comKalshi will allow bets on selected clinical trial results and full FDA decisions, starting with Phase 3 studies from established companies. The FDA separately approved Merck's Lipfendra cholesterol pill based on studies showing up to 60% LDL reduction.